Genascence Corporation is a clinical stage life sciences company developing gene therapies for prevalent musculoskeletal and joint diseases. The Company’s lead candidate (GNSC-001) is a recombinant adeno-associated viruses (rAAV) vector expressing human IL-1Ra to inhibit IL-1 and is poised to be the first gene therapy in osteoarthritis (OA).
Status: Active
Announcement Date: January 2022
